Abstracts tagged "immunology"

Abstract Number: 1565 • ACR Convergence 2022
Dissection of Ocular and Peripheral Blood Immune Phenotypes Suggests Preferential Transmigration of CD16+ Monocytes to Effector Sites in Behçet’s Disease
Yesim Ozguler¹, Ziyan Lin², Ann Cavers³, gulen Hatemi⁴, Olivier Manches⁵ and Johannes Nowatzky³, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, New York, NY, ²NYU Grossman School of Medicine, NYU Langone Applied Informatics Laboratories, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁵Recherche et Développement, Immunobiology and Immunotherapy in Chronic Diseases, Institute for Advanced Biosciences, Inserm U 1209, CNRS UMR 5309, Université Grenoble Alpes Etablissement Français du Sang Auvergne-Rhône-Alpes, Grenoble, France
Background/Purpose: Cellular immunity of Behçet's Disease (BD) remains poorly understood. Previous work has provided clues pointing to most innate and adaptive immune cell types in…
Abstract Number: 1742 • ACR Convergence 2022
Shared Epitope Allomorphs Directly Influence Antigen-specific T-cell Responses in RA
Ravi Kumar¹, Anatoly Dubnovitsky¹, Christina Gerstner¹, Niyaz Yoosuf², Sara Turcinov¹, Sanjay Boddul¹, Fredrik Wermeling¹, Lars Klareskog¹, Leonid Padyukov¹ and vivianne malmström¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Bioinvent International AB, Lund, Sweden
Background/Purpose: The products of rheumatoid arthritis (RA)-associated MHC class II risk alleles HLA-DRB1*04:01 and *04:04 (DR4) differ only by two amino acids in the peptide…
Abstract Number: 2186 • ACR Convergence 2022
Cellular and Humoral Responses Following SARS-CoV-2 mRNA Vaccination in Patients on PD-1 Immunotherapy with irAEs
Sokratis Apostolidis¹, Paulina Coutifaris², Mark Painter³, Ajinkya Pattekar², Rishi Goel¹, divij mathew², Wenzhao Meng², Kevin Wang², Bria Fulmer², Angela Corrigan², Kendall Lundgreen², Elizabeth Drapeau², Derek Oldridge², Josephine Giles², Amy Baxter², Sasikanth Manne², Michelle Mckeague², Ahron Flowers², Oliva Kuthuru², Sherea Long², Jeanette Dougherty², Sigrid Gouma², Justine Williams², Maura McLaughlin², Sharon Adamski², Alba Grifoni⁴, Daniela Weiskopf⁴, Alessandro Sette⁴, Scott Hensley², Paul Bates², Eline Luning Prak¹, Laura Vella², Giorgos Karakousis², Ravi Amaravadi², Suzanne McGettigan², Kristin Kreider², Tara Mitchell², Allison Greenplate², Lynn Schuchter², Alexander Huang² and E. John Wherry¹, ¹University of Pennsylvania, Philadelphia, PA, ²UPenn, Philadelphia, ³UPenn, Philadelphia, PA, ⁴LJI, La Jolla
Background/Purpose: Patients with cancer exhibit increased mortality from SARS-CoV-2 infection compared to the general population. SARS-CoV-2 mRNA vaccination in healthy individuals generates effective and long-lasting…
Abstract Number: 0300 • ACR Convergence 2022
Exposure-Response Analyses of Upadacitinib Effects on Plasma Biomarkers in Rheumatoid Arthritis Patients
Yuli Qian¹, Fang Cai², Thierry Sornasse³, Jie Shen¹, Heidi Camp⁴ and Mohamed-Eslam Mohamed¹, ¹AbbVie, Inc., North Chicago, IL, ²AbbVie, Redwood City, CA, ³AbbVie, South San Francisco, CA, ⁴Abbvie, Winnetka, IL
Background/Purpose: Upadacitinib (UPA) is an oral Janus kinase (JAK) inhibitor approved for the treatment of moderately-to-severely active rheumatoid arthritis (RA). Previous investigations demonstrated UPA modulates…
Abstract Number: 0648 • ACR Convergence 2022
Pathogenic Anti-C1q Antibodies Potentiate Activation of the Classical Complement Pathway in a Subset of Lupus Nephritis Patients
Edmund Chang¹, Julian Low², Ellen Cahir-McFarland², Henk-Andre Kroon², Yaisa Andrews-Zwilling², Ted Yednock² and Ann Mongan², ¹Annexon Biosciences, Brisbane, CA, ²Annexon Biosciences, South San Francisco, CA
Background/Purpose: In LN, excess immune complexes lead to nephrotic deposition of C1q and C4d, the latter of which has been correlated with circulating C4d and…
Abstract Number: 0806 • ACR Convergence 2022
Long-term Effectiveness of Sublingual Polybacterial Vaccines in Patients with Systemic Autoimmune Disease and Active Pharmacological Immunosuppression
Inés Pérez Sancristóbal¹, María Paula Álvarez Hernández², Silvia Sanchez - Ramon³, Cristina Martinez⁴, Eduardo de la Fuente³, Concepcion Morado⁴, Dalifer Freites Nuñez², Benjamin Fernandez Gutierrez⁵ and Gloria Candelas⁴, ¹Instituto de Investigación Sanitaria San Carlos, Rheumatology, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain, ³Department of Clinical Immunology, IML and IdSSC, Hospital Clínico San Carlos, Madrid, Spain, ⁴Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁵Hospital Clínico San Carlos, Rheumatology Deparment, Madrid, Spain
Background/Purpose: Infections in patients with systemic autoimmune disease (SAD) are associated with immune dysfunction, disease activity and immunosuppression. Synthetic and biologic disease-modifying drugs (DMARDs) have…
Abstract Number: 1570 • ACR Convergence 2022
Memory CD4+T Cell Signature Is Associated with Unfavorable Prognosis in IgG4-related Disease: Risk Stratification by Machine-learning
Yuxue Nie¹, zheng liu¹, Wei Cao², Taisheng Li² and Wen Zhang³, ¹Department of Rheumatology, Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Department of Infectious Diseases, Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ³Peking Union Medical College Hospital, Beijing, China
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic immune-mediated disease with significant heterogeneity. A better understanding of the variance in the immune signature of IgG4-RD will…
Abstract Number: 1743 • ACR Convergence 2022
Identification of Immune Cell Types in the Peripheral Blood of Rheumatoid Arthritis Patients Associated with Susceptibility and Response to Treatment
Maria Christofi¹, Ben Mulhearn², Lysette Marshall¹, Megan Sutcliffe¹, Darren Plant¹, Kimme Hyrich¹, Ann Morgan³, Anthony Wilson⁴, John D Isaacs⁵, Soumya Raychaudhuri⁶, Anne Barton¹ and Sebastien Viatte¹, ¹The University of Manchester, Manchester, United Kingdom, ²Royal United Hospital Bath | University of Bath, Bath, United Kingdom, ³University of Leeds, Leeds, United Kingdom, ⁴University College Dublin, Dublin, Ireland, ⁵Institute for Translational and Clinical Research, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) is a complex immune mediated disease that affects 1% of the population. Even with modern therapeutic strategies, many patients with RA…
Abstract Number: 2195 • ACR Convergence 2022
Pre-exposure Prophylaxis for SARS-CoV-2 with Subcutaneous Casirivimab/Imdevimab in Vaccine-refractory Patients with Immune-mediated Inflammatory Diseases
Filippo Fagni¹, Katja Schmidt², Daniela Bohr³, Larissa Valor Mendez⁴, Ioanna Minopoulou², Melek Yalcin Mutlu², Fabian Hartmann², Koray Tascilar⁴, Karin Manger⁵, Bernhard Manger², Arnd Kleyer⁴, David Simon⁴, Georg Schett⁶ and Thomas Harrer², ¹University Hospital Erlangen; Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ²University Hospital Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology, Erlangen, Germany, ³Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and University Hospital Erlangen, Erlangen, Germany, ⁴Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054 Erlangen, Germany; Deutsches Zentrum Immuntherapie, Friedrich-Alexander-UniversityErlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Rheumatology Practice Bamberg, Bamberg, Germany, ⁶Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: Humoral responses to SARS-CoV-2 vaccination are reduced in patients with immune-mediated inflammatory diseases (IMID), especially when treated with B-cell depletion therapies, leading to increased…
Abstract Number: L02 • ACR Convergence 2021
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Ines Colmegna¹, Mariana Useche¹, Emmanouil Rampakakis², Nathalie Amiable³, Emmanuelle Rollet-Labelle³, Louis Bessette⁴, Jo-Anne Costa⁴, Marc Dionne⁴, Mary-Ann Fitzcharles², Elizabeth Hazel², Deirdre McCormack², Laetitia Michou⁴, Pantelis Panopalis², Marc-Andre Langlois⁵, Sasha Bernatsky⁶ and Paul R. Fortin⁷, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Centre de Recherche du CHU de Quebec, Quebec, Canada, ⁴Universite Laval, Quebec, QC, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷CHU de Quebec - Universite Laval, Quebec, Canada
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
Abstract Number: L20 • ACR Convergence 2021
Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA) Who Had Failed High-Dose Glucocorticoids (GCs)
Fabrizio De Benedetti¹, Alexei Grom², Paul Brogan³, Claudia Bracaglia¹, Manuela Pardeo¹, Giulia Marucci¹, Despina Eleftheriou³, Charalampia Papadopoulou³, Pierre Quartier⁴, Jordi Antón⁵, Rikke Frederiksen⁶, Veronica Asnaghi⁶ and Cristina De Min⁶, ¹Bambino Gesù Children's Hospital IRCCS, Rome, Italy, ²Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, ³UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁴Université de Paris, IMAGINE Institute, RAISE reference centre, Pediatric Immuno-Hematology and Rheumatology Unit, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁵Hospital Sant Joan de Déu, Division of Pediatric Rheumatology, University of Barcelona, Barcelona, Spain, ⁶Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland
Background/Purpose: MAS is a life-threatening complication of rheumatic diseases, occurring most frequently in sJIA. The mainstay of MAS treatment is high dose GCs; however, GCs…
Abstract Number: 0059 • ACR Convergence 2021
Deep Immune Cell Profiling of Tissue Microenvironment Using Imaging Mass Cytometry in Psoriatic Disease
Lihi Eder¹, Stephane Caucheteux¹, Somi Afiuni², Adriana Krizova¹, James Limacher¹, Hartland Jackson¹ and Vincent Piguet¹, ¹University of Toronto, Toronto, ON, Canada, ²Lunenfeld Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada
Background/Purpose: Cross talk between different cell types, such as T cell subsets and other immune cell populations, is important in psoriatic disease. Imaging Mass Cytometry…
Abstract Number: 0993 • ACR Convergence 2021
The Mechanistic Basis of anti-CD6 as a Novel Form for the Treatment of Autoimmune Diseases and Cancer
Mikel Gurrea-Rubio¹, Jeffrey Ruth¹, Qi Wu¹, Eliza Pei-Suen Tsou¹, Phillip Campbell¹, Peggy Randon¹, M.Asif Amin¹, Nora Singer², Feng Lin³ and David Fox¹, ¹University of Michigan, Ann Arbor, MI, ²The MetroHealth System, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: The use of Immune Checkpoint Inhibitors (ICIs) is limited by the induction of immune-related adverse events. CD6 is expressed by most T lymphocytes and…
Abstract Number: 1772 • ACR Convergence 2021
Autologous EBV-specific Cytotoxic T Cells in Systemic Lupus Erythematosus: An Innovative Phase I/IIa Clinical Trial
Antoine Enfrein¹, Beatrice Clemenceau², Soraya Saiagh³, Céline Bressollette⁴, Zahir Amoura⁵, Henri Vie² and Mohamed Hamidou¹, ¹Médecine interne, CHU de Nantes, Nantes, France, ²Inserm U1232, Université de Nantes, Nantes, France, ³Unité de Thérapie Cellulaire et Génique, CHU de Nantes, Nantes, France, ⁴Laboratoire de Virologie, CHU de Nantes, Nantes, France, ⁵Médecine interne, Hôpital Pitié Salpêtrière, AP-HP, Paris, France
Background/Purpose: Epstein-Barr Virus (EBV) has been suggested as a potential environmental factor in systemic lupus erythematosus (SLE) onset and disease activity. Here, we report the…
Abstract Number: 0113 • ACR Convergence 2021
Reactogenicity of the SARS-CoV-2 Vaccines Associates with Immunogenicity in Patients with Autoimmune and Inflammatory Disease
Monica Yang¹, Kimberly E. Taylor¹, Diana Paez¹, Alex Carividi¹, Emanuel Demissie¹, Niti Pawar¹, Alia A. El-Qunni,², Lily E. McMorrow², Rebecca E. Schriefer², Katherine Huang², Baylee Kinnett², Wooseob Kim², Ali H Ellebedy², Matthew Ciorba², Michael Paley³, Parakkal Deepak², Alfred Kim², Patricia Katz¹, Mehrdad Matloubian¹, Mary Nakamura⁴ and Lianne Gensler⁵, ¹University of California San Francisco, San Francisco, CA, ²Washington University School of Medicine, St. Louis, MO, ³Washington University in St. Louis, Olivette, MO, ⁴UCSF/SFVAHCS, San Francisco, CA, ⁵Department of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Little is known about the reactogenicity and related SARS-CoV-2 vaccine response in patients with chronic inflammatory disease (CID). While researchers have hypothesized increased symptomatology…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].